Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats.

Adenosine receptor antagonists, DMPX, PACPX and theophylline, produce contralateral rotations in unilateral 6-hydroxydopamine-lesioned rats. DMPX and theophylline markedly increase rotations produced by bromocriptine (a dopamine D2 receptor agonist) and/or SKF38393A (a dopamine D1 receptor agonist). All of these effects are inhibited by CGS21680C (an adenosine A2 receptor agonist). These findings suggest synergistic interactions among D1, D2 and A2 receptors that may be relevant to the treatment of Parkinson's disease.

• Publication year

  1993

• Venue

  Brain Research

• Publication date

  1993-06-11

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/0006-8993(93)90925-DPMID 8186990
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Caffeine produces contralateral rotation in rats with unilateral dopamine denervation: comparisons with apomorphine-induced responses

  2004cited by this paper
• Dopamine denervation leads to an increase in the intramembrane interaction between adenosine A2 and dopamine D2 receptors in the neostriatum.

  1992cited by this paper
• Postsynaptic dopamine/adenosine interaction: I. Adenosine analogues inhibit dopamine D2-mediated behaviour in short-term reserpinized mice.

  1991cited by this paper
• ADENOSINE RECEPTOR AGONISTS AND ANTAGONISTS

  1991cited by this paper
• Early development of levodopa‐induced dyskinesias and response fluctuations in young‐onset Parkinson's disease

  1991cited by this paper
• Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.

  1991cited by this paper
• Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats.

  1991cited by this paper
• Effect of Unilateral Perinatal Hypoxic‐Ischemic Brain Injury in the Rat on Dopamine D1 and D2 Receptors and Uptake Sites: A Quantitative Autoradiographic Study

  1991cited by this paper
• Striatal Restricted Adenosine A2 Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry Study

  1991cited by this paper
• D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons.

  1990cited by this paper
• Rotational behaviour induced by theophylline in 6-OHDA nigrostriatal denervated rats is dependent on the supersensitivity of striatal dopaminergic receptors.

  1989cited by this paper
• Adverse Effects of Levodopa in Parkinson’s Disease

  1989cited by this paper
• Relationship between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway.

  1989cited by this paper
• Effects of mu receptor agonists and droperidol on motor coordination in mice.

  1988cited by this paper
• Specific D1 and D2 dopamine agonists have synergistic effects in the 6-hydroxydopamine circling model in the rat.

  1988cited by this paper
• 3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo antagonist of adenosine analogs.

  1988cited by this paper
• Synergistic effects of D1 and D2 dopamine agonists on turning behaviour in rats.

  1986cited by this paper
• Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

  1986cited by this paper
• Adenosine — a selective neuromodulator in the mammalian CNS?

  1984cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper
• Adenosine receptors and behavioral actions of methylxanthines.

  1981cited by this paper
• Pharmacological and biochemical evidence for the dopamine agonistic effect of bromocriptine.

  1978cited by this paper
• STIMULANT PROPERTIES OF BROMOCRIPTINE ON CENTRAL DOPAMINE RECEPTORS IN COMPARISON TO APOMORPHINE, (+)‐AMPHETAMINE AND l‐DOPA

  1976cited by this paper
• Effect of some phosphodiesterase inhibitors on central dopamine mechanisms.

  1976cited by this paper
• Action of caffeine and theophyllamine on supersensitive dopamine receptors: considerable enhancement of receptor response to treatment with DOPA and dopamine receptor agonists.

  1974cited by this paper
• Effect of coffee ingestion on catecholamine release.

  1969cited by this paper
• Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine.

  1962cited by this paper

• Osteoprotective Effects of Melatonin on Bone Loss Associated with Dopaminergic Neuron Degeneration in a Rat Model of Parkinson Disease

  2025cites this paper
• Toxin-Induced Animal Models of Parkinson's Disease.

  2024cites this paper
• Striatal glutamatergic hyperactivity in Parkinson's disease.

  2022cites this paper
• Dopamine D4 receptor modulates inhibitory transmission in pallido‐pallidal terminals and regulates motor behavior

  2020cites this paper
• Investigating metabolomics and the effects of oxyresveratrol in experimental Parkinson's disease

  2019cites this paper
• Study of the Neuropeptide Function in Parkinson’s Disease Using the 6-Hydroxydopamine Model of Experimental Hemiparkinsonism

  2017cites this paper
• Early synaptic dysfunction in Parkinson's disease: Insights from animal models

  2016cites this paper
• Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent.

  2016cites this paper
• Viral vector-based models of Parkinson's disease.

  2015cites this paper
• 1‐[2‐(4‐Benzyloxyphenoxy)Ethyl]Imidazole inhibits monoamine oxidase B and protects against neuronal loss and behavioral impairment in rodent models of Parkinson's disease

  2015cites this paper
• Striatal Injury with 6-OHDA Transiently Increases Cerebrospinal GFAP and S100B

  2015cites this paper
• Implications fonctionnelles de la tVTA dans le contrôle des systèmes dopaminergiques mésencéphaliques

  2015cites this paper
• Rôle de Lmx1a et de Lmx1b dans la maintenance des circuits dopaminergiques chez la souris adulte

  2015cites this paper
• Animal Models for PD and ALS

  2014cites this paper
• Modèle progressif de la maladie de parkinson après dysfonctionnement aigu des transporteurs du glutamate dans la substance noire chez le rat.

  2013cites this paper
• Characterisation of embryonic ventral mesencephalon grafts in a rat model of Parkinson’s disease

  2013cites this paper
• Dopamine D4 receptor stimulation in GABAergic projections of the globus pallidus to the reticular thalamic nucleus and the substantia nigra reticulata of the rat decreases locomotor activity.

  2012cites this paper
• Etude des mécanismes moléculaires impliqués dans l'infiltration cérébrale des lymphocytes T dans la maladie de Parkinson

  2012cites this paper
• Investigation of the antidyskinetic site of action of metabotropic and ionotropic glutamate receptor antagonists. Intracerebral infusions in 6-hydroxydopamine-lesioned rats with levodopa-induced dyskinesia.

  2012cites this paper
• Purinergic Signalling in the Central Nervous System

  2012cites this paper
• A(2A)/D(2) receptor heteromerization in a model of Parkinson's disease. Focus on striatal aminoacidergic signaling.

  2012cites this paper
• Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease

  2011cites this paper
• A guide to neurotoxic animal models of Parkinson's disease.

  2011cites this paper
• Mechanisms of aluminium neurotoxicity in oxidative stress-induced degenerative processes in relation to parkinson's disease

  2011cites this paper
• A tale on animal models of Parkinson's disease

  2011cites this paper
• Purinergic signalling: from normal behaviour to pathological brain function.

  2011cites this paper
• Adenosine and ATP receptors in the brain.

  2011cites this paper
• Blockade of adenosine A2A receptors downregulates DARPP-32 but increases ERK1/2 activity in striatum of dopamine deficient "weaver" mouse.

  2010cites this paper
• Caffeine use in children: what we know, what we have left to learn, and why we should worry.

  2009cites this paper
• Neuropharmacological studies of Parkinson´s disease with some emphasis on serotonin transmission

  2008cites this paper
• Interaction of dopamine and adenosine receptor function in behavior: studies with dopamine-deficient mice.

  2008cites this paper
• Rodent Toxin Models of PD: An Overview

  2008cites this paper
• Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6‐hydroxydopamine‐lesioned rats treated with D1 or D2 dopamine receptor agonists

  2008cites this paper
• Postmenopausal effects of intrastriatal estrogen on catalepsy and pallidal electroencephalogram in an animal model of Parkinson's disease.

  2008cites this paper
• La cafeína en la enfermedad de Parkinson

  2008cites this paper
• An update on the mechanisms of the psychostimulant effects of caffeine

  2008cites this paper
• The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat

  2008cites this paper
• [Caffeine in Parkinson's disease].

  2008cites this paper
• Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.

  2007cites this paper
• Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease

  2007cites this paper
• The 6-Hydroxydopamine model of parkinson’s disease

  2007cites this paper
• Motor complications in Parkinson's disease and the clinical significance of rotational behavior in the rat: have we wasted our time?

  2006cites this paper
• Parkinson’s Disease, the Dopamine System and Immediate Early Genes

  2006cites this paper
• Reversion of levodopa‐induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6‐OHDA‐lesioned rats

  2006cites this paper
• Time-Course of Brain Oxidative Damage Caused by Intrastriatal Administration of 6-Hydroxydopamine in a Rat Model of Parkinson’s Disease

  2006cites this paper
• Pharmacological Properties and Neurophsysiological Effects of Caffeine

  2006cites this paper
• Caffeine and activation theory : effects on health and behavior

  2006cites this paper
• New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.

  2005cites this paper
• New adenosine A2A receptor antagonists: actions on Parkinson's disease models.

  2005cites this paper
• Toxin-induced models of Parkinson’s disease

  2005cites this paper
• Neurodegenerative Diseases: Toxic animal models

  2005cites this paper
• Caffeine as a psychomotor stimulant: mechanism of action

  2004cites this paper
• Simultaneous Blockade of Adenosine A2A and Metabotropic Glutamate mGlu5 Receptors Increase their Efficacy in Reversing Parkinsonian Deficits in Rats

  2004cites this paper
• Cellular pathology of Parkinson’s disease: astrocytes, microglia and inflammation

  2004cites this paper
• Parkinson's Disease Mechanisms and Models

  2003cites this paper
• Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats

  2003cites this paper
• Gene knockout approach to adenosine A2A receptors in Parkinson's disease

  2003cites this paper
• Potential nondopaminergic drugs for Parkinson's disease.

  2003cites this paper
• Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons

  2003cites this paper
• Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease.

  2003cites this paper
• Adenosine–dopamine interactions

  2003cites this paper
• Adenosine A2A antagonism reverses levodopa‐induced motor alterations in hemiparkinsonian rats

  2002cites this paper
• Different Patterns of Behavior and Gene Expression Induced by Chronic L-Dopa and A2A Antagonists Plus L-Dopa Treatments in 6- Hydroxydopamine Lesioned Rats

  2002cites this paper
• Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic‐intermittent L‐dopa and A2A receptor blockade plus L‐Dopa in dopamine‐denervated rats

  2002cites this paper
• Dopamine — Adenosine Interactions

  2002cites this paper
• Distribution of adenosine A(2A) receptor antagonist KW-6002 and its effect on gene expression in the rat brain.

  2002cites this paper
• Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat.

  2002cites this paper
• Modulation by adenosine A2A receptors of dopamine‐mediated motor behavior as a basis for antiparkinson’s disease drugs

  2001cites this paper
• SCH 58261, an A2A adenosine receptor antagonist, counteracts parkinsonian‐like muscle rigidity in rats

  2001cites this paper
• Adenosine A2A receptor antagonists: Potential therapeutic and neuroprotective effects in parkinson’s disease

  2001cites this paper
• Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate‐putamen of rats

  2001cites this paper
• Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease.

  2001cites this paper
• Adenosine receptor signaling in vitro and in vivo

  2001cites this paper
• Methylxanthines reverse the adipsic and aphagic syndrome induced by bilateral 6-hydroxydopamine lesions of the nigrostriatal pathway in rats.

  2000cites this paper
• Adenosine A(2A) receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats.

  2000cites this paper
• Selective Adenosine A2AReceptor Antagonism as an Alternative Therapy for Parkinson's Disease

  2000cites this paper
• Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors.

  2000cites this paper
• Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine‐denervated striatum

  2000cites this paper
• Lack of synergism between caffeine and SKF 38393 on rotational behavior in 6-hydroxydopamine-denervated rats.

  2000cites this paper
• Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys

  1999cites this paper
• Distribution, biochemistry and function of striatal adenosine A2A receptors.

  1999cites this paper
• Theophylline increases “on” time in advanced parkinsonian patients

  1999cites this paper
• Modulation of endogenous GABA release by an antagonistic adenosine A1 / dopamine D1 receptor interaction in rat brain limbic regions but not basal ganglia

  1999cites this paper
• Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons.

  1999cites this paper
• Repeated co-administration of caffeine and bromocriptine prevents tolerance to the effects of caffeine in the turning behavior animal model.

  1999influential citation
• Motor effects induced by a blockade of adenosine A2A receptors in the caudate‐putamen

  1998cites this paper
• Cellular distribution of adenosine A2A receptor mrna in the primate striatum

  1998cites this paper
• Potential of Adenosine A2A Receptor Antagonists in the Treatment of Movement Disorders

  1998cites this paper
• Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas.

  1997cites this paper
• The role of dopamine in the behavioral effects of caffeine in animals and humans.

  1997cites this paper
• Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.

  1997cites this paper
• Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.

  1997cites this paper
• Antagonism of adenosine A2A receptors underlies the behavioural activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens.

  1997cites this paper
• Dopamine–Adenosine Interactions in the Striatum and the Globus Pallidus: Inhibition of Striatopallidal Neurons through Either D2 or A2A Receptors Enhances D1Receptor-Mediated Effects on c-fos Expression

  1997cites this paper
• Blockade of A2a Adenosine Receptors Positively Modulates Turning Behaviour and c‐Fos Expression Induced by D1 Agonists in Dopamine‐denervated Rats

  1996cites this paper
• The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists

  1996cites this paper
• Comparison of the effects of prototypical behavioral stimulants on locomotor activity and rotational behavior in rats.

  1996cites this paper
• Systemic and intrastriatal theophylline have opposite effects on dopamine and dopamine metabolites measured by intrastriatal microdialysis in the rat.

  1996cites this paper
• Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents.

  1996cites this paper
• Adenosine and the nervous system: clinical implications.

  1996cites this paper